Literature DB >> 10100866

Prevention of alphaII(b)beta3 activation by non-steroidal antiinflammatory drugs.

C Domínguez-Jiménez1, F Díaz-González, I González-Alvaro, J M Cesar, F Sánchez-Madrid.   

Abstract

We have studied the effect of non-steroidal antiinflammatory drugs (NSAIDs) on alphaII(b)beta3 integrin activation and platelet aggregation. NSAIDs such as meloxicam, piroxicam, indomethacin and aspirin, but not aceclofenac or diclofenac interfered with the activation state of alphaII(b)beta3. NSAIDs that inhibited alphaII(b)beta3 activation were also able both to partially inhibit platelet primary aggregation and to accelerate platelet deaggregation. These effects of NSAIDs were not dependent on cyclooxygenase inhibition. The results obtained indicate that some NSAIDs exert a specific action on alphaII(b)beta3 activation, and provide an additional mechanism that accounts for their beneficial effects in diseases in which platelet activation is involved.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10100866     DOI: 10.1016/s0014-5793(99)00236-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  4 in total

Review 1.  Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions.

Authors:  Anetta Undas; Kathleen E Brummel-Ziedins; Kenneth G Mann
Journal:  Blood       Date:  2006-12-05       Impact factor: 22.113

Review 2.  Aspirin resistance and genetic polymorphisms.

Authors:  Josie A Cambria-Kiely; Pritesh J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2002-08       Impact factor: 2.300

Review 3.  NSAIDs: learning new tricks from old drugs.

Authors:  Federico Díaz-González; Francisco Sánchez-Madrid
Journal:  Eur J Immunol       Date:  2015-01-21       Impact factor: 5.532

4.  Lack of influence of the COX inhibitors metamizol and diclofenac on platelet GPIIb/IIIa and P-selectin expression in vitro.

Authors:  Dirk Scheinichen; Holger-Andreas Elsner; Rodin Osorio; Björn Jüttner; Werner Gröschel; Karsten Jaeger; Siegfried Piepenbrock
Journal:  BMC Anesthesiol       Date:  2004-04-23       Impact factor: 2.217

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.